Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2002

View Archived Issues

IND submitted for nitroglycerin lingual spray

Positive pharmacokinetic results for buccal desmopressin

Tacrolimus for psoriasis scheduled for marketing within three to four years

YC-1 may be useful for treating erectile dysfunction

GenStar to develop delivery vectors for Centocor

Chugai discusses business plan for Roche alliance

Improved pharmacological profile reported for CHF-4227.01 in postmenopausal osteoporosis

Bazedoxifene compares favorably with other SERMs in ovariectomized rat model of bone loss

New SERM from Pfizer may set the standard for therapy of menopausal disorders

Truncated peptide analogues of SDF-1 designed with significant biological activity

Barcelona-based researchers take major step towards a cure for type 1 diabetes

Antisense ODN directed against the human androgen receptor inhibits prostate tumor growth

Antex updates progress of AP-158

BioAstin improves condition of patients with carpal tunnel syndrome

Encouraging early clinical results announced for GnRH antagonist

Onconase inhibits RNA viruses including HIV-1

HuMax-CD4 provides long-lasting effects in phase II psoriasis trial

Shire inlicenses mesalazine MMX technology for ulcerative colitis

Avanir seeks approval for docosanol 10% cream in Sweden

JTC-801 representative of a new class of analgesics

Initiation of phase II trial of SMART anti-gamma interferon antibody in Crohn's disease

New treatments for diabetes and related disorders claimed by AstraZeneca

Hungarian biotech company identifies new MDR modulators

Alpha1-adrenoceptor antagonists useful for urological disorders

Progesterone receptor modulators in the Bayer pipeline

Potent and selective alpha4 integrin inhibitors useful for inflammatory conditions

AstraZeneca presents new NOS inhibitors and therapeutic applications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...